换一批非小细胞肺癌免疫治疗疗效预测新指标——LIPI评分系统
A new predictor of the efficacy of immunotherapy for non-small cell lung cancer—lung immune prognostic index (LIPI)
摘要免疫检查点抑制剂已被证实可显著提高多种恶性肿瘤患者的生存率，因此需要寻找有效的疗效预测指标来指导免疫治疗。肺免疫预后指数(LIPI)是近期发展起来的预测非小细胞肺癌免疫治疗疗效的新指标。基线LIPI能够识别免疫治疗潜在获益人群，是一种方便有效的预后预测指标。
更多相关知识
abstractsImmune checkpoint inhibitors have demonstrated the ability to significantly improve survival across a range of cancers. So predictive markers are required to guide treatment decisions. The lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. The pre-treatment LIPI is a convenient prognostic marker able to identify ICIs-treated patient groups with significantly different survival and response outcomes.
More相关知识
关键词
癌，非小细胞肺预后免疫检查点抑制剂肺免疫预后指数Carcinoma, non-small-cell lungPrognosisImmune checkpoint inhibitorLung immune prognostic index
栏目名称
DOI
10.3760/cma.j.cn371439-20190926-00023
发布时间
2026-03-31（万方平台首次上网日期，不代表论文的发表时间）
- 浏览197
- 被引3
- 下载247
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
